Gilead Sciences Epclusa

Description

Active Ingredient: This medicine contains a combination of ingredients Sofosbuvir / Velpatasvir. Sofosbuvir is a nucleoside analog and potent inhibitor of the hepatitis C virus RNA polymerase that is used in with other antiviral agents to treat chronic hepatitis C. An antiviral therapy of hepatitis C with this drug and other direct-acting agents in people with cirrhosis is occasionally complicated by hepatic decompensation. This treatment can cause reactivation of hepatitis B in susceptible people coinfected with the hepatitis B virus.

Velpatasvir is an inhibitor of the hepatitis C virus nonstructural protein 5A replication complex, with potential activity against HCV genotypes 1-6. It appears to bind to the domain I of the NS5A protein. This inhibits the activity of the NS5A protein and leads to the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication.

Indications: Given medication is a combination of two active ingredients sofosbuvir and velpatasvir and is indicated to treat chronic hepatitis C, a viral infection of the liver. It is used with another antiviral medication that works by reducing the amount of hepatitis C virus in the body. Epclusa helps the immune system fight the infection and may help the liver recover. This infection can induce serious liver problems like scarring or liver cancer.

Action Mechanism: Mentioned medication works by weakening the activity of proteins needed by hepatitis C. One of the two drugs in Epclusa is sofosbuvir, a nucleotide polymerase inhibitor, and the other is velpatasvir, which is an NS5A hepatitis C virus nonstructural protein 5A inhibitor.

Dosages: This combination of two active ingredients made available in a dosage as given below:

• 400mg/100mg: It should be taken orally once a day with or without food as advised by the doctor

Note: A person needs frequent blood tests to check liver function while treating with this medicine.